Corporate News

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that it has received its latest research unit order for a Polarean 9820 Xenon Polariser system from the University of Kansas Medical Center ("KUMC").

KUMC is a major research and teaching hospital (see: www.kumc.edu) and this polariser will form the cornerstone of a new hyperpolarised 129Xe imaging research programme. Following receipt of this order, the Company now has a total of 25 polarisers either installed or on order.

Richard Hullihen, CEO of Polarean, said: "We are delighted to begin our relationship with KUMC and look forward to a long and mutually beneficial work programme which will aim to expand the clinical and public health frontiers of hyperpolarised xenon imaging."

Polarean products are currently being used at a number of research sites on a pre-FDA clearance basis to facilitate the research and evaluation of lung function. For more information on the Polarean 9820 129Xe Hyperpolariser see: http://www.polarean.com/129Xe_hyperpolarizer_9820.html

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

Polarean Imaging plc	www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer	Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy	Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001